Dapagliflozin vs empagliflozin
Dapagliflozin and empagliflozin are the two most used SGLT2 inhibitors. Both are off patent in India. This page brings together our reports on each, and on studies that looked at both.
Studies that looked at both
None of our reports so far has covered a study of both. This list updates itself when one is published.
Dapagliflozin
- Oral orforglipron vs dapagliflozin on metformin: ACHIEVE-2 HbA1c results postedTrial registry · 18 October 2026
- Oral safiglipron versus dapagliflozin in type 2 diabetes: phase 3 trial in ChinaRandomised trial · 10 October 2026
Empagliflozin
No reports yet.
For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 18 October 2026.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.